Stiefel psoriasis drug gains additional FDA approval

 RESEARCH TRIANGLE PARK, N.C. — The Food and Drug Administration has approved a treatment for psoriasis of the scalp made by a subsidiary of British drug maker GlaxoSmithKline.

Stiefel announced Friday the approval of Sorilux (calcipotriene) foam for psoriasis of the scalp in adults. The drug was already approved for psoriasis of other parts of the body in October 2010.

"Studies have shown that in at least 50% of psoriasis cases, the scalp is involved," Stiefel medicines development leader for dermatology research and development Susan Learned said. "We believe this additional indication for Sorilux foam will help meet the needs of both patients and physicians."

Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.